Drug intelligence / Profile preview

HL231 Solution for Inhalation

Development stage: Phase 3
Lead developer: Haisco Pharmaceutical Group
Modality: Small Molecules
Administration: Inhalation

Overview

HL231 Solution for Inhalation is a fixed-dose combination of indacaterol (261μg) and glycopyrrolate (141μg) administered once daily via PARI BOY nebulizer. It is being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The drug is currently in Phase 3 clinical trials comparing its efficacy and safety against Ultibro in Chinese patients with moderate to very severe COPD.

Other names: indacaterol maleate + glycopyrronium bromide inhalation solutionindacaterol + glycopyrronium

Targets

CHRM2 (M2)M1 (Muscarinic acetylcholine receptor M1)CHRM3 (M3)ADRB2 (β2)

Beyond the preview

Go deeper on HL231 Solution for Inhalation.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL231 Solution for Inhalation.

Explore the full profile